Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

Perimeter reaches regulatory milestone with FDA PMA submission for next-gen B-Series OCT with ImgAssist AI 2.0

Perimeter Medical Imaging AI (TSXV:PINK; OTCQX:PYNKF) announced that it has filed a premarket approval (PMA) application for its next-generation B-Series OCT system, which combines proprietary AI technology with optical...

March 17, 2025

Developments

Biovica partners with Outcomes4Me to support HR-positive mBC patients

Biovica International (STO:BIOVIC-B; FRA:911) announced that it has partnered with Outcomes4Me to support post-menopausal patients with hormone (HR)-positive metastatic breast cancer (mBC) in understanding treatment...

March 12, 2025

Executive Moves

Matinas names Keith Murphy and Edward Neugeboren to BOD

Matinas BioPharma (NYSE American:MTNB) has appointed biotech industry veterans Keith Murphy and Edward Neugeboren to its board of directors (BOD) as independent members, effective today. Also effective today, Matinas...

March 11, 2025

Developments

Atossa announces plan to pursue MBC indication for (Z)-endoxifen

Atossa Therapeutics (NASDAQ:ATOS) announced its decision to pursue a metastatic breast cancer (MBC) indication for (Z)-endoxifen. According to Attosa, it also plans to work with the FDA to advance additional...

March 11, 2025

Developments

Trevi reports positive Phase 2a trial data of Haduvio for RCC

Trevi Therapeutics (NASDAQ:TRVI) announced positive topline results from its Phase 2a RIVER study of oral nalbuphine ER (Haduvio) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF)...

March 10, 2025

Developments

PDS launches Phase 3 trial for HNSCC

PDS Biotechnology (NASDAQ:PDSB) announced that it has commenced its Phase 3 trial, VERSATILE-003, to evaluate the efficacy and safety of Versamune HPV plus pembrolizumab for head and neck squamous cell carcinoma (HNSCC)...

March 10, 2025

Developments

Covenant Health Fort Sanders first in Tennessee to use Perimeter’s pioneering AI-driven OCT cancer margin visualization technology

Perimeter Medical Imaging AI (TSX-V:PINK; OTCQX:PYNKF) announced that Covenant Health Fort Sanders Regional is the first hospital in Tennessee to implement its optical coherence technology (OCT) technology, S-Series...

March 6, 2025

Developments

Oragenics submits IB for Phase 2 trial of ONP-002 in mTBI

Oragenics (NYSE American:OGEN) announced the submission of an Investigator Brochure (IB) in preparation for its Phase 2 trial evaluating ONP-002 for mild traumatic brain injury (mTBI), commonly known as concussion...

March 6, 2025

Developments

SIR accepts Autonomix abstract showcasing study results

Autonomix Medical (NASDAQ:AMIX) announced that the Society of Interventional Radiology (SIR) has accepted its abstract highlighting its technology and early proof-of-concept study results for a poster presentation at...

March 6, 2025

Developments

EPO to grant Moleculin’s Annamycin new patent allowances strengthening global exclusivity

Moleculin Biotech (NASDAQ:MBRX) announced that it received a Notice of Intent to Grant from the European Patent Office (EPO) for its patent application covering Annamycin, a potential next-generation, non-cardiotoxic...

March 6, 2025

Developments

Arch announces non-brokered private placement

Arch BioPartners (TXSV:ARCH; QTCQB:ACHFF) has arranged a non-brokered private placement of 225,806 common shares at $1.55 per share, generating proceeds of CAD $350,000. According to Arch, the offering, set to close...

March 5, 2025

Developments

ASBrS selects Perimeter’s B-Series OCT with ImgAssist AI 2.0 pivotal trial results for presentation at 2025 annual meeting

Perimeter Medical Imaging AI (TSXV:PINK; OTCQX:PYNKF) announced that detailed results from its pivotal trial evaluating the next-generation B-Series OCT with ImgAssist AI 2.0 for breast-conserving surgery (BCS) will be...

March 5, 2025

Subscribe